 2. Received two lines of prior therapy that includes an IMiD lenalidomide or thalidomide and a proteasome inhibitor bortezomib andor carfilzomib used either separately or in combination. a. Prior pomalidomide therapy is permitted, provided the patient achieved at least a partial remission and had not progressed for 3 months after stopping therapy. 